Prosaptide TX14 A

Drug Profile

Prosaptide TX14 A

Alternative Names: Prosaposin-derived peptide; Prosaptide™

Latest Information Update: 26 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Myelos Corporation
  • Class Analgesics; Nerve growth factors
  • Mechanism of Action Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies; Neuropathic pain

Most Recent Events

  • 26 Mar 2008 Discontinued - Phase-II for Neuropathic pain in USA (SC)
  • 12 Jan 2006 Development of prosaptide TX14 A has been discontinued
  • 11 Mar 2005 Discontinued - Phase-II for Neuropathic pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top